{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T09:05:49Z","timestamp":1777799149837,"version":"3.51.4"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2006,2,7]],"date-time":"2006-02-07T00:00:00Z","timestamp":1139270400000},"content-version":"vor","delay-in-days":5304,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biopharm &amp; Drug Disp"],"published-print":{"date-parts":[[1991,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Since plasma exchange (PE) represents a major treatment for patients suffering from systemic diseases, its influence on the kinetics of three drugs was investigated: vidarabine, used in patients with polyarteritis nodosa associated with hepatitis B virus (eight subjects), and diclofenac and paracetamol for investigative purposes (five subjects). This study confirmed that vidarabine is so rapidly deaminated to form hypoxanthine arabinoside (Hx\u2010Ara) that no detectable concentrations were measured. Hx\u2010Ara levels were used to evaluate vidarabine kinetics; 19\u00b75 \u00b1 14\u00b76 mg of Hx\u2010Ara were removed by one PE during the first week of treatment (15 mg kg<jats:sup>\u22121<\/jats:sup> d<jats:sup>\u22121<\/jats:sup>, continuous infusion) and 7\u00b78 \u00b1 10\u00b72 mg were eliminated by one PE during the second week of treatment (7\u00b75 mg kg<jats:sup>\u22121<\/jats:sup> d<jats:sup>\u22121<\/jats:sup>, continuous infusion). Based on the vidarabine intake per hour and the resulting quantity of Hx\u2010Ara removed per hour, PE recovery was quite important (ca. 30 per cent), during both the first and second weeks of continuous infusion. Data were subject to large interindividual variability. However, these results do not favor vidarabine dosage supplementation in this indication because the duration of PE is less than 8 per cent of a daily administration period. For paracetamol (1 g, single oral dose) and diclofenac (100 mg, single oral dose), the fractions of drug removed during PE effected within 2 h of drug intake, were respectively 5\u00b70 \u00b1 3\u00b71 per cent and 13\u00b76 \u00b1 9\u00b75 per cent, while plasmapheretic clearance reached, respectively, 13\u00b70 \u00b1 10\u00b77 per cent of the systemic clearance for paracetamol and 23\u00b70 \u00b1 1\u00b70 per cent for diclofenac.<\/jats:p>","DOI":"10.1002\/bdd.2510120603","type":"journal-article","created":{"date-parts":[[2006,10,14]],"date-time":"2006-10-14T12:46:00Z","timestamp":1160829960000},"page":"411-424","source":"Crossref","is-referenced-by-count":16,"title":["Diclofenac, paracetamol, and vidarabine removal during plasma exchange in polyarteritis nodosa patients"],"prefix":"10.1002","volume":"12","author":[{"given":"F.","family":"Fauvelle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Leon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Perret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Petitjean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Guillevin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,2,7]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-94-6-820_2"},{"key":"e_1_2_1_3_2","first-page":"27","volume-title":"Plasma Exchange","author":"Arsac P. H.","year":"1980"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1982.107"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/jca.2920030303"},{"key":"e_1_2_1_6_2","first-page":"264","volume":"16","author":"Sabto J.","year":"1981","journal-title":"Clin. Nephrol."},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1985.tb02843.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002808101501215"},{"key":"e_1_2_1_9_2","first-page":"827","volume-title":"Progress in Artificial Organs","author":"Guillevin L.","year":"1986"},{"key":"e_1_2_1_10_2","first-page":"487","volume":"6","author":"Ouzan D.","year":"1985","journal-title":"Plasma Ther. Transfus. Technol."},{"key":"e_1_2_1_11_2","first-page":"225","volume":"14","author":"Jones J. V.","year":"1985","journal-title":"Dialysis Transplant."},{"key":"e_1_2_1_12_2","first-page":"305","volume":"5","author":"Sketris I. S.","year":"1984","journal-title":"Plasma Ther. Transfus. Technol."},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.6.1276"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00544567"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00568201"},{"key":"e_1_2_1_16_2","first-page":"219","volume-title":"Handbook of Basic Pharmacokinetics","author":"Ritschel W. A.","year":"1980"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1980.98"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)84296-6"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)84226-7"},{"key":"e_1_2_1_20_2","first-page":"487","volume":"229","author":"Said A.","year":"1981","journal-title":"Arzneim. Forsch."},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198510060-00004"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/148.4.721"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198020040-00002"},{"key":"e_1_2_1_24_2","first-page":"111","volume-title":"Adenine Arabinoside: An Antiviral Agent","author":"Glazko A. J.","year":"1975"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.18.1.212"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1978242154"},{"key":"e_1_2_1_27_2","unstructured":"M.RowlandandT. N.Tozer inClinical Pharmacokinetics: Concepts and Applications Lea and Febiger (Eds) 1989 p.438."}],"container-title":["Biopharmaceutics &amp; Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdd.2510120603","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.2510120603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T23:26:51Z","timestamp":1698017211000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.2510120603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,8]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1991,8]]}},"alternative-id":["10.1002\/bdd.2510120603"],"URL":"https:\/\/doi.org\/10.1002\/bdd.2510120603","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,8]]}}}